All news
A new antimalarial candidate with a novel mechanism of action has demonstrated efficacy in mouse models of falciparum and vivax malaria.
MMV will contribute intellectual property to the Pool for Open Innovation Against Neglected Tropical Diseases.
MMV and Ferrer, one of Spain’s major pharmaceutical groups, have agreed to explore the Ferrer compound library for promising molecules that could be developed into novel medicines needed to defeat malaria.
MMV and Malawi Ministry of Health sow the seeds for a fruitful collaboration.
Through access to AstraZeneca’s extensive compound library, MMV will seek to identify promising compounds with the potential to treat malaria.
In an unprecedented move, data from three new projects supported by MMV have been made available in the public domain.
The Global Fund is looking for experts to serve on its Technical Review Panel. The experts must have sound technical knowledge and extensive program experience in HIV/AIDS, TB or malaria.
MMV and California based Anacor Pharmaceuticals have agreed to explore Anacor’s novel boron chemistry platform for developing new therapeutics for the treatment of malaria.
MMV’s Director, Global Access, Ambrose Talisuna, has been profiled in The Lancet as a powerful advocate for access to effective antimalarial treatments.
MMV, Pfizer and LSHTM collaborate to develop a new combination dose of azithromycin and chloroquine phosphate as Intermittent Preventive Therapy for pregnant women.
- 1 of 15
- ››
